Back to resultsRandomized Trial to Examine a Differential Therapeutic Response in Symptomatic Patients With Non-obstructive Coronary Artery Disease (EXAMINE-CAD)
Primary Purpose
Coronary Microvascular Dysfunction, Microvascular Angina, Vasospasm, Coronary
Status
Recruiting
Phase
Phase 4
Locations
International
Study Type
Interventional
Intervention
Bisoprolol
Diltiazem
Placebo
Sponsored by
About this trial
This is an interventional treatment trial for Coronary Microvascular Dysfunction focused on measuring Coronary Microvascular Dysfunction, Microvascular Angina, Coronary Vasospasm, Vasospastic Angina, Beta Blocker, Calcium Channel Blocker
Eligibility Criteria
Inclusion Criteria:
- Age 18 - 85 years
- Recurrent angina symptoms provoked by exercise and/or repeated attacks of angina at rest (both at least for 4 weeks)
- Absence of flow-limiting coronary artery stenosis (as defined by any coronary artery diameter reduction >50% or fractional flow reserve ≤0.80)
- Left ventricular ejection fraction (LVEF) >50%
- Written informed consent
Exclusion Criteria:
- Pregnancy, planned pregnancy, or breast-feeding
- Female patients of childbearing potential who are unwilling to use a highly effective contraception method during trial participation according to CTFG. In addition, a negative serum or urine pregnancy test must be available prior to randomization.
- Expected life expectancy <1 year
- Contraindications to withholding nitrates, calcium channel blockers, and beta blockers for 48 hours before invasive coronary reactivity testing (e.g. clinical need for rate control in case of permanent atrial fibrillation, recurrent angina symptoms without any possibility to wihthold ongoing medication)
- Known hypersensitivity or contraindication to bisoprolol or diltiazem or any of its excipients.
- Concomitant therapy with systemic drugs that are strong inhibitors of both CYP3A4 and P-gp (azole antimycotics such as ketoconazole and itraconazole or HIV protease inhibitors such as ritonavir)
- Concomitant therapy with drugs that are strong CYP3A4 inducers (e.g. carbamazepine, phenytoin, rifampicin, St. John's wort)
- Bradycardia (<50/min) at time of randomization
- Symptomatic hypotension (<100 mmHg) at time of randomization
- Cardiogenic shock
- Second and third degree atrioventricular block, sick sinus syndrome, sinoatrial block
- Severe valvular heart disease (grade III)
- Any cardiomyopathy including those with preserved left ventricular ejection fraction (LVEF)
- Chronic obstructive pulmonary disease
- Severe bronchial asthma
- Metabolic acidosis at time of randomization
- Renal failure (creatinine >2.0 mg/dL)
- N-terminal pro B-type natriuretic peptide (NT-proBNP) >300 ng/L
- Known significant liver disease (e.g. acute hepatitis, chronic active hepatitis, cirrhosis) which is associated with moderate or severe hepatic impairment (alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) ≥2.0 upper limit of normal (ULN))
- Untreated pheochromocytoma
- Late stage of peripheral arterial disease or Raynaud's syndrome
- Participation in another clinical trial according to AMG or MPG at the time of randomization and the duration of this trial
- Patients who are unwilling to consent to saving and propagation of pseudonymized medical data for study reasons
- Persons who are legally detained in an official institution
- Persons likely to not be available to complete all protocol-required study visits or procedures, and/or to comply with all required study procedures to the best of patient's and investigator's knwoledge
- Persons who may dependent on the Sponsor, the Investigator or the trial sites, are not eligible to enter the trial
- Active coronavirus disease 2019 (COVID-19) at time of randomization
Sites / Locations
- Kerckhoff-Klinik gGmbH
- Herz- und Diabeteszentrum NRW
- Charité University Medicine Berlin, Campus Benjamin FranklinRecruiting
- Universitätsklinikum Erlangen
- Universitätsklinikum Frankfurt
- Universitäres Herz- und Gefäßzentrum UKE Hamburg
- Universitätsklinikum Heidelberg
- Universitätsklinikum Schleswig-Holstein, Campus Kiel
- Universitätsklinikum Leipzig
- Universitätsmedizin der Johannes Gutenberg-Universität Mainz
- Universitätsmedizin Mannheim
- Deutsches Herzzentrum München des Freistaates Bayern - Klinik an der Technischen Universität München
- Robert-Bosch-Krankenhaus
- Inselspital, Universitätsspital Bern
- Universitäres Herzzentrum Zürich, Universitätsspital Zürich
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Arm 6
Arm Type
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
Arm Label
bisoprolol first, diltiazem second
bisoprolol first, placebo second
diltiazem first, bisoprolol second
diltiazem first, placebo second
placebo first, bisoprolol second
placebo first, diltiazem second
Arm Description
Crossover Design: bisoprolol first, diltiazem second, placebo third
Crossover Design: bisoprolol first, placebo second, diltiazem third
Crossover Design: diltiazem first, bisoprolol second, placebo third
Crossover Design: diltiazem first, placebo second, bisoprolol third
Crossover Design: placebo first, bisoprolol second, diltiazem third
Crossover Design: placebo first, diltiazem second, bisoprolol third
Outcomes
Primary Outcome Measures
Change in angina symptom severity as measured by the Seattle Angina Questionnaire (SAQ) summary score from each period specific baseline to the end of this period (week 4)
Assessment of angina symptom severity as measured by the SAQ summary score resulting from the SAQ physical limitation scale, SAQ angina frequency scale, and SAQ quality of life scale. The score ranges from 0 to 100, with the lower the score, the higher the symptom severity and limitations.
Secondary Outcome Measures
SAQ angina stability scale
Individual SAQ domain to evaluate the disease-specific health status with quantification of patients' symptoms of angina. The score ranges from 0 to 100, with the lower the score, the higher the symptom severity and limitations.
SAQ angina frequency scale
Individual SAQ domain to evaluate the disease-specific health status with quantification of patients' symptoms of angina. The score ranges from 0 to 100, with the lower the score, the higher the symptom severity and limitations.
SAQ treatment satisfaction scale
Individual SAQ domain to evaluate the disease-specific treatment satisfaction. The score ranges from 0 to 100, with the higher the score, the higher the treatment satisfaction.
SAQ physical limitation scale
Individual SAQ domain to evaluate the disease-specific health status with quantification of patients' symptoms of angina and the extent to which their angina affects their functioning. The score ranges from 0 to 100, with the lower the score, the higher the symptom severity and limitations.
SAQ quality of life
Individual SAQ domain to evaluate the disease-specific health status with the extent to which their angina affects their quality of life. The score ranges from 0 to 100, with the higher the score, the higher the quality of life.
Duke Activity Status Index (DASI)
Assessment of functional capacity of patients with cardiovascular disease
Rose dyspnea scale
Assessment of patients' dyspnea level with common activities. Scores range from 0 to 4, where 0 indicates no dyspnea with activity and 4 indicates significant limitations due to dyspnea.
Angina diary (Angina episodes per week)
Assessment of angina frequency
Angina diary (nitroglycerin use per week))
Assessment of need for nitroglycerine
Quality of Life (Short Form 36 health survey questionnaire)
Evaluation of health-related quality of life
Psychological symptoms as assessed by Patient Health Questionnaire (PHQ-9)
Assessment of symptoms for depression in patients with physical illness or physical complaints
Psychological symptoms as assessed by the Hospital Anxiety Depression Scale (HADS))
Assessment of symptoms for depression and anxiety in patients with physical illness or physical complaints
Functional capacity as assessed by bicycle exercise testing
Assessment of functional capacity in bicycle exercise testing (i.e. maximum load capacity in watt)
Full Information
NCT ID
NCT05294887
First Posted
February 28, 2022
Last Updated
March 15, 2022
Sponsor
Charite University, Berlin, Germany
Collaborators
Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)
1. Study Identification
Unique Protocol Identification Number
NCT05294887
Brief Title
Randomized Trial to Examine a Differential Therapeutic Response in Symptomatic Patients With Non-obstructive Coronary Artery Disease
Acronym
EXAMINE-CAD
Official Title
First Prospective Randomized Trial to Examine a Differential Therapeutic Response in Symptomatic Patients With Non-obstructive Coronary Artery Disease After Coronary Physiological Testing
Study Type
Interventional
2. Study Status
Record Verification Date
March 2022
Overall Recruitment Status
Recruiting
Study Start Date
March 4, 2022 (Actual)
Primary Completion Date
June 2024 (Anticipated)
Study Completion Date
June 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Charite University, Berlin, Germany
Collaborators
Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
EXAMINE-CAD-DZHK22 is a prospective, randomized, double-blind, placebo-controlled, crossover trial investigating the efficacy of beta blocker (bisoprolol) and calcium channel blocker (diltiazem) therapy in symptomatic patients with non-obstructed coronary arteries according to coronary physiological testing results.
Detailed Description
Patients presenting with recurrent angina but non-obstructed coronary arteries are increasingly recognized and have a high morbidity and symptomatic burden. These patients are often misdiagnosed and discharged without further investigation or treatment. Current European Society of Cardiology (ESC) guidelines for the management of patients with chronic coronary syndromes recommend beta blockers or calcium channel blockers, depending on the presence of abnormal vasodilatation or abnormal vasoconstriction. Scientific evidence to support this recommendation, however, is scarce and no randomized clinical trial of this differential therapy has been performed in these patients. The aim of the EXAMINE-CAD-DZHK22 trial is therefore to compare for the first time the efficacy of beta blocker (bisoprolol) and calcium channel blocker (diltiazem) therapy in reducing angina symptoms in symptomatic patients with non-obstructed coronary arteries according to coronary physiology testing results. This study is the first to investigate whether coronary physiology testing can guide therapeutic management of these patients depending on whether abnormalities of vasodilatation or vasoconstriction are present. The EXAMINE-CAD-DZHK22 trial will thus fill an important knowledge and evidence gap in the treatment of these highly symptomatic patients, and has the potential to pave the way for future large-scale clinical trials in symptomatic patients with non-obstructed coronary arteries.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Coronary Microvascular Dysfunction, Microvascular Angina, Vasospasm, Coronary, Vasospastic Angina, Prinzmetal Angina, Coronary Artery Disease
Keywords
Coronary Microvascular Dysfunction, Microvascular Angina, Coronary Vasospasm, Vasospastic Angina, Beta Blocker, Calcium Channel Blocker
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Crossover Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Masking Description
Subjects will be randomly assigned to 1 of 6 possible treatment sequences. All treatment sequences will include the consecutive treatment with bisoprolol, diltiazem, and placebo.
Allocation
Randomized
Enrollment
132 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
bisoprolol first, diltiazem second
Arm Type
Experimental
Arm Description
Crossover Design: bisoprolol first, diltiazem second, placebo third
Arm Title
bisoprolol first, placebo second
Arm Type
Experimental
Arm Description
Crossover Design: bisoprolol first, placebo second, diltiazem third
Arm Title
diltiazem first, bisoprolol second
Arm Type
Experimental
Arm Description
Crossover Design: diltiazem first, bisoprolol second, placebo third
Arm Title
diltiazem first, placebo second
Arm Type
Experimental
Arm Description
Crossover Design: diltiazem first, placebo second, bisoprolol third
Arm Title
placebo first, bisoprolol second
Arm Type
Experimental
Arm Description
Crossover Design: placebo first, bisoprolol second, diltiazem third
Arm Title
placebo first, diltiazem second
Arm Type
Experimental
Arm Description
Crossover Design: placebo first, diltiazem second, bisoprolol third
Intervention Type
Drug
Intervention Name(s)
Bisoprolol
Other Intervention Name(s)
beta blocker
Intervention Description
beta-adrenergic receptor blocker
Intervention Type
Drug
Intervention Name(s)
Diltiazem
Intervention Description
calcium channel blocker
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Placebo
Primary Outcome Measure Information:
Title
Change in angina symptom severity as measured by the Seattle Angina Questionnaire (SAQ) summary score from each period specific baseline to the end of this period (week 4)
Description
Assessment of angina symptom severity as measured by the SAQ summary score resulting from the SAQ physical limitation scale, SAQ angina frequency scale, and SAQ quality of life scale. The score ranges from 0 to 100, with the lower the score, the higher the symptom severity and limitations.
Time Frame
from each period specific baseline to the end of this period, i.e. baseline and 4 weeks; 6 weeks and 10 weeks; 12 weeks and 16 weeks
Secondary Outcome Measure Information:
Title
SAQ angina stability scale
Description
Individual SAQ domain to evaluate the disease-specific health status with quantification of patients' symptoms of angina. The score ranges from 0 to 100, with the lower the score, the higher the symptom severity and limitations.
Time Frame
from each period specific baseline to the end of this period, i.e. baseline and 4 weeks; 6 weeks and 10 weeks; 12 weeks and 16 weeks
Title
SAQ angina frequency scale
Description
Individual SAQ domain to evaluate the disease-specific health status with quantification of patients' symptoms of angina. The score ranges from 0 to 100, with the lower the score, the higher the symptom severity and limitations.
Time Frame
from each period specific baseline to the end of this period, i.e. baseline and 4 weeks; 6 weeks and 10 weeks; 12 weeks and 16 weeks
Title
SAQ treatment satisfaction scale
Description
Individual SAQ domain to evaluate the disease-specific treatment satisfaction. The score ranges from 0 to 100, with the higher the score, the higher the treatment satisfaction.
Time Frame
from each period specific baseline to the end of this period, i.e. baseline and 4 weeks; 6 weeks and 10 weeks; 12 weeks and 16 weeks
Title
SAQ physical limitation scale
Description
Individual SAQ domain to evaluate the disease-specific health status with quantification of patients' symptoms of angina and the extent to which their angina affects their functioning. The score ranges from 0 to 100, with the lower the score, the higher the symptom severity and limitations.
Time Frame
from each period specific baseline to the end of this period, i.e. baseline and 4 weeks; 6 weeks and 10 weeks; 12 weeks and 16 weeks
Title
SAQ quality of life
Description
Individual SAQ domain to evaluate the disease-specific health status with the extent to which their angina affects their quality of life. The score ranges from 0 to 100, with the higher the score, the higher the quality of life.
Time Frame
from each period specific baseline to the end of this period, i.e. baseline and 4 weeks; 6 weeks and 10 weeks; 12 weeks and 16 weeks
Title
Duke Activity Status Index (DASI)
Description
Assessment of functional capacity of patients with cardiovascular disease
Time Frame
from each period specific baseline to the end of this period, i.e. baseline and 4 weeks; 6 weeks and 10 weeks; 12 weeks and 16 weeks
Title
Rose dyspnea scale
Description
Assessment of patients' dyspnea level with common activities. Scores range from 0 to 4, where 0 indicates no dyspnea with activity and 4 indicates significant limitations due to dyspnea.
Time Frame
from each period specific baseline to the end of this period, i.e. baseline and 4 weeks; 6 weeks and 10 weeks; 12 weeks and 16 weeks
Title
Angina diary (Angina episodes per week)
Description
Assessment of angina frequency
Time Frame
from each period specific baseline to the end of this period, i.e. baseline and 4 weeks; 6 weeks and 10 weeks; 12 weeks and 16 weeks
Title
Angina diary (nitroglycerin use per week))
Description
Assessment of need for nitroglycerine
Time Frame
from each period specific baseline to the end of this period, i.e. baseline and 4 weeks; 6 weeks and 10 weeks; 12 weeks and 16 weeks
Title
Quality of Life (Short Form 36 health survey questionnaire)
Description
Evaluation of health-related quality of life
Time Frame
from each period specific baseline to the end of this period, i.e. baseline and 4 weeks; 6 weeks and 10 weeks; 12 weeks and 16 weeks
Title
Psychological symptoms as assessed by Patient Health Questionnaire (PHQ-9)
Description
Assessment of symptoms for depression in patients with physical illness or physical complaints
Time Frame
from each period specific baseline to the end of this period, i.e. baseline and 4 weeks; 6 weeks and 10 weeks; 12 weeks and 16 weeks
Title
Psychological symptoms as assessed by the Hospital Anxiety Depression Scale (HADS))
Description
Assessment of symptoms for depression and anxiety in patients with physical illness or physical complaints
Time Frame
from each period specific baseline to the end of this period, i.e. baseline and 4 weeks; 6 weeks and 10 weeks; 12 weeks and 16 weeks
Title
Functional capacity as assessed by bicycle exercise testing
Description
Assessment of functional capacity in bicycle exercise testing (i.e. maximum load capacity in watt)
Time Frame
from baseline (visit 1) to the end of each treatment period (4 weeks, 10 weeks, 16 weeks)
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Age 18 - 85 years
Recurrent angina symptoms provoked by exercise and/or repeated attacks of angina at rest (both at least for 4 weeks)
Absence of flow-limiting coronary artery stenosis (as defined by any coronary artery diameter reduction >50% or fractional flow reserve ≤0.80)
Left ventricular ejection fraction (LVEF) >50%
Written informed consent
Exclusion Criteria:
Pregnancy, planned pregnancy, or breast-feeding
Female patients of childbearing potential who are unwilling to use a highly effective contraception method during trial participation according to CTFG. In addition, a negative serum or urine pregnancy test must be available prior to randomization.
Expected life expectancy <1 year
Contraindications to withholding nitrates, calcium channel blockers, and beta blockers for 48 hours before invasive coronary reactivity testing (e.g. clinical need for rate control in case of permanent atrial fibrillation, recurrent angina symptoms without any possibility to wihthold ongoing medication)
Known hypersensitivity or contraindication to bisoprolol or diltiazem or any of its excipients.
Concomitant therapy with systemic drugs that are strong inhibitors of both CYP3A4 and P-gp (azole antimycotics such as ketoconazole and itraconazole or HIV protease inhibitors such as ritonavir)
Concomitant therapy with drugs that are strong CYP3A4 inducers (e.g. carbamazepine, phenytoin, rifampicin, St. John's wort)
Bradycardia (<50/min) at time of randomization
Symptomatic hypotension (<100 mmHg) at time of randomization
Cardiogenic shock
Second and third degree atrioventricular block, sick sinus syndrome, sinoatrial block
Severe valvular heart disease (grade III)
Any cardiomyopathy including those with preserved left ventricular ejection fraction (LVEF)
Chronic obstructive pulmonary disease
Severe bronchial asthma
Metabolic acidosis at time of randomization
Renal failure (creatinine >2.0 mg/dL)
N-terminal pro B-type natriuretic peptide (NT-proBNP) >300 ng/L
Known significant liver disease (e.g. acute hepatitis, chronic active hepatitis, cirrhosis) which is associated with moderate or severe hepatic impairment (alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) ≥2.0 upper limit of normal (ULN))
Untreated pheochromocytoma
Late stage of peripheral arterial disease or Raynaud's syndrome
Participation in another clinical trial according to AMG or MPG at the time of randomization and the duration of this trial
Patients who are unwilling to consent to saving and propagation of pseudonymized medical data for study reasons
Persons who are legally detained in an official institution
Persons likely to not be available to complete all protocol-required study visits or procedures, and/or to comply with all required study procedures to the best of patient's and investigator's knwoledge
Persons who may dependent on the Sponsor, the Investigator or the trial sites, are not eligible to enter the trial
Active coronavirus disease 2019 (COVID-19) at time of randomization
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Aslihan Erbay, MD
Phone
+49 30 450 513 653
Email
examine-cad@charite.de
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ulf Landmesser, Prof. Dr.
Organizational Affiliation
Charité University, Berlin, Germany
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Barbara E Stähli, Prof. Dr.
Organizational Affiliation
Universitätsspital Zürich
Official's Role
Study Chair
Facility Information:
Facility Name
Kerckhoff-Klinik gGmbH
City
Bad Nauheim
ZIP/Postal Code
61231
Country
Germany
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Roland Klingenberg, PD Dr.
Facility Name
Herz- und Diabeteszentrum NRW
City
Bad Oeynhausen
ZIP/Postal Code
32545
Country
Germany
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Tanja Rudolph, Prof. Dr.
Facility Name
Charité University Medicine Berlin, Campus Benjamin Franklin
City
Berlin
ZIP/Postal Code
12203
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ulf Landmesser, Prof. Dr.
Facility Name
Universitätsklinikum Erlangen
City
Erlangen
ZIP/Postal Code
91054
Country
Germany
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Luise Gaede, PD Dr.
Facility Name
Universitätsklinikum Frankfurt
City
Frankfurt
ZIP/Postal Code
60590
Country
Germany
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Stephan Fichtlscherer, Prof. Dr.
Facility Name
Universitäres Herz- und Gefäßzentrum UKE Hamburg
City
Hamburg
ZIP/Postal Code
20246
Country
Germany
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Peter Clemmensen, Prof. Dr.
Facility Name
Universitätsklinikum Heidelberg
City
Heidelberg
ZIP/Postal Code
69120
Country
Germany
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Manuela Licka, Dr.
Facility Name
Universitätsklinikum Schleswig-Holstein, Campus Kiel
City
Kiel
ZIP/Postal Code
24105
Country
Germany
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Matthias Lutz, PD Dr.
Facility Name
Universitätsklinikum Leipzig
City
Leipzig
ZIP/Postal Code
04103
Country
Germany
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Karsten Lenk, PD Dr.
Facility Name
Universitätsmedizin der Johannes Gutenberg-Universität Mainz
City
Mainz
ZIP/Postal Code
55131
Country
Germany
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Tommaso Gori, Prof. Dr.
Facility Name
Universitätsmedizin Mannheim
City
Mannheim
ZIP/Postal Code
68167
Country
Germany
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ibrahim Akin, Prof. Dr.
Facility Name
Deutsches Herzzentrum München des Freistaates Bayern - Klinik an der Technischen Universität München
City
München
ZIP/Postal Code
80636
Country
Germany
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jens Wiebe, PD Dr.
Facility Name
Robert-Bosch-Krankenhaus
City
Stuttgart
ZIP/Postal Code
70376
Country
Germany
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ong Peter, Prof. Dr.
Facility Name
Inselspital, Universitätsspital Bern
City
Bern
ZIP/Postal Code
3010
Country
Switzerland
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Lorenz Räber, Prof. Dr.
Facility Name
Universitäres Herzzentrum Zürich, Universitätsspital Zürich
City
Zürich
ZIP/Postal Code
8091
Country
Switzerland
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Barbara Stähli, Prof. Dr.
12. IPD Sharing Statement
Learn more about this trial
Randomized Trial to Examine a Differential Therapeutic Response in Symptomatic Patients With Non-obstructive Coronary Artery Disease
We'll reach out to this number within 24 hrs